Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension

Heart. 2013 Oct;99(19):1415-20. doi: 10.1136/heartjnl-2012-303549. Epub 2013 Jul 11.

Abstract

Objective: To examine the effect of balloon pulmonary angioplasty (BPA) on chronic thromboembolic pulmonary hypertension (CTEPH) in patients with inoperable disease or persistent pulmonary hypertension after pulmonary endarterectomy.

Design: Observational cohort study.

Setting: Referred patients with inoperable or persistent CTEPH.

Patients: Twenty consecutive CTEPH patients (10 females), aged 60±10 years.

Interventions bpa main outcome measures: Right heart catheterisation, functional capacity (cardiopulmonary exercise testing (CPET) and NYHA class) and blood sampled biomarkers N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T examined at the time of diagnosis and repeated in all patients 3 months after the last BPA.

Results: Seventy-three catheterisations were performed with 18.6±6.1 BPAs per patient on segmental and subsegmental arteries. Two deaths occurred following the first BPA, with an overall 10% periprocedural death rate. Reperfusion oedema complicated seven procedures. Comparisons before and after BPA showed significant haemodynamic improvements, including decreased mean pulmonary artery pressure (mPAP) (45±11 mm Hg vs 33±10 mm Hg; p<0.001) and increased cardiac output (4.9±1.6 L/min vs 5.4±1.9 L/min; p=0.011). Reduced right ventricular strain was indicated by significantly lower plasma levels of NT-proBNP and troponin T. Significant improvement in functional capacity was evident as assessed by NYHA class (3.0±0.5 vs 2.0±0.5; p<0.001) and CPET (13.6±5.6 mL/kg/min vs 17.0±6.5 mL/kg/min; p<0.001). Seventeen patients (85%) were alive after 51±30 months of follow-up.

Conclusions: BPA may offer an alternative form of treatment in selected CTEPH patients. While prognostic markers such as haemodynamics, functional capacity and biomarkers improve, significant periprocedural complications must be recognised. Randomised trials are warranted.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Angioplasty, Balloon* / adverse effects
  • Angioplasty, Balloon* / mortality
  • Arterial Pressure
  • Biomarkers / blood
  • Cardiac Catheterization
  • Cardiac Output
  • Chronic Disease
  • Endarterectomy
  • Exercise Test
  • Exercise Tolerance
  • Female
  • Humans
  • Hypertension, Pulmonary / blood
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / mortality
  • Hypertension, Pulmonary / physiopathology
  • Hypertension, Pulmonary / surgery
  • Hypertension, Pulmonary / therapy*
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood
  • Norway
  • Peptide Fragments / blood
  • Predictive Value of Tests
  • Prospective Studies
  • Pulmonary Embolism / blood
  • Pulmonary Embolism / diagnosis
  • Pulmonary Embolism / mortality
  • Pulmonary Embolism / physiopathology
  • Pulmonary Embolism / surgery
  • Pulmonary Embolism / therapy*
  • Recovery of Function
  • Time Factors
  • Treatment Outcome
  • Troponin T / blood
  • Ventricular Function, Right

Substances

  • Biomarkers
  • Peptide Fragments
  • Troponin T
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain